Cyclerion Therapeutics Stock Today
| CYCN Stock | USD 4.17 0.12 2.96% |
Performance7 of 100
| Odds Of DistressOver 71
|
Cyclerion Therapeutics is selling at 4.17 as of the 10th of December 2024; that is 2.96 percent increase since the beginning of the trading day. The stock's open price was 4.05. Cyclerion Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 10th of November 2024 and ending today, the 10th of December 2024. Click here to learn more.
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system diseases. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. The company has 2.71 M outstanding shares of which 5.5 K shares are currently shorted by private and institutional investors with about 0.78 trading days to cover. More on Cyclerion Therapeutics
Cyclerion Stock Highlights
| President | Regina Graul |
| Business Concentration | Pharmaceutical Products, Biotechnology, Healthcare, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Cyclerion Therapeutics (CYCN) is traded on NASDAQ Exchange in USA. It is located in 245 First Street, Riverview II, Cambridge, MA, United States, 02142 and employs 1 people. Cyclerion Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 11.3 M. Cyclerion Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.71 M outstanding shares of which 5.5 K shares are currently shorted by private and institutional investors with about 0.78 trading days to cover.
Cyclerion Therapeutics currently holds about 30.32 M in cash with (21.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.7.
Check Cyclerion Therapeutics Probability Of Bankruptcy
Ownership AllocationThe market capitalization of Cyclerion Therapeutics is $11.3 Million. Cyclerion Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check Cyclerion Ownership Details
Cyclerion Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Cyclerion Therapeutics market risk premium is the additional return an investor will receive from holding Cyclerion Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0804 | |||
| Jensen Alpha | 3.45 | |||
| Total Risk Alpha | (2.40) | |||
| Sortino Ratio | 0.2966 |
Cyclerion Stock Against Markets
Cyclerion Therapeutics Corporate Management
| Todd Milne | Senior Innovation | Profile | |
| Cheryl Gault | Chief Officer | Profile | |
| Jessica Rennekamp | Associate Communications | Profile | |
| Rhonda CPA | Chief Officer | Profile | |
| Christopher Winrow | Sr Lead | Profile | |
| Jennifer Chickering | Director Strategy | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cyclerion Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Cyclerion Stock, please use our How to Invest in Cyclerion Therapeutics guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cyclerion Therapeutics. If investors know Cyclerion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cyclerion Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Cyclerion Therapeutics is measured differently than its book value, which is the value of Cyclerion that is recorded on the company's balance sheet. Investors also form their own opinion of Cyclerion Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Cyclerion Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cyclerion Therapeutics' market value can be influenced by many factors that don't directly affect Cyclerion Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cyclerion Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cyclerion Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cyclerion Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.